Apogee Therapeutics (APGE) Operating Leases (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Operating Leases data on file, last reported at $4.9 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $4.9 million, down 37.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.9 million (down 37.39% YoY), and the FY2025 annual result was $5.3 million, down 37.83% from the prior year.
• Operating Leases eased to $4.9 million in Q1 2026 per APGE's latest filing, from $5.3 million in the prior quarter.
• Over five years, Operating Leases peaked at $9.3 million in Q3 2024 and troughed at $630000.0 in Q1 2024.
• A 4-year average of $5.4 million and a median of $5.6 million in 2025 frame the typical range for Operating Leases.
• On a YoY basis, Operating Leases climbed as much as 1144.44% in 2025 and fell as far as 37.91% in 2025.
• A 4-year view of Operating Leases shows it stood at $933000.0 in 2023, then jumped by 821.44% to $8.6 million in 2024, then tumbled by 37.83% to $5.3 million in 2025, then decreased by 8.16% to $4.9 million in 2026.
• Business Quant data shows APGE's Operating Leases at $4.9 million in Q1 2026, $5.3 million in Q4 2025, and $5.8 million in Q3 2025.